$1.27
12.39%
Nasdaq, Fri, Aug 22 2025
ISIN
US00887A1051
Symbol
ALRN

Aileron Therapeutics, Inc. Stock price

$1.27
-0.11 7.97% 1M
-1.10 46.41% 6M
-1.03 44.78% YTD
-1.23 49.20% 1Y
-2.73 68.25% 3Y
-22.33 94.62% 5Y
-214.73 99.41% 10Y
-214.73 99.41% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.14 12.39%
ISIN
US00887A1051
Symbol
ALRN
Industry

Key metrics

Basic
Market capitalization
$29.6m
Enterprise Value
$23.9m
Net debt
positive
Cash
$5.7m
Shares outstanding
23.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
0.6
Financial Health
Equity Ratio
87.5%
Return on Equity
-115.6%
ROCE
-123.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-61.4m | -
EBIT
$-61.3m | $-23.6m
Net Income
$-59.2m | $-21.6m
Free Cash Flow
$-21.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-141.6% | -
EBIT
-140.4% | 16.2%
Net Income
-134.5% | 65.6%
Free Cash Flow
17.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.4
FCF per Share
$-0.9
Short interest
1.1%
Employees
-
Rev per Employee
-
Show more

Is Aileron Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Aileron Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aileron Therapeutics, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aileron Therapeutics, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Aileron Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.96 9.96
39% 39%
-
- Research and Development Expense 14 14
56% 56%
-
-61 -61
142% 142%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -61 -61
140% 140%
-
Net Profit -59 -59
135% 135%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aileron Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

Head office United States
CEO Brian Windsor
Founded 2001
Website www.reintx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today